Showing results (541-550 of 587) with videos related to

Sort By:
Pageof 59
Lancet (London, England)|January 19, 2016
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)Fabrice Barlesi, Julien Mazieres, Jean-Philippe Merlio, et al.
European Journal of Cancer (Oxford, England : 1990)|March 16, 2020
The 2016-2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical studyJean-Marie Michot, Ariane Lappara, Jérôme Le Pavec, et al.
The Lancet. Oncology|April 1, 2020
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trialJosé Trigo, Vivek Subbiah, Benjamin Besse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2022
Comprehensive Genome Profiling in Patients With Metastatic Non-Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 TrialFabrice Barlesi, Pascale Tomasini, Maryam Karimi, et al.
The Lancet. Oncology|February 24, 2015
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trialNaiyer A Rizvi, Julien Mazières, David Planchard, et al.
JCO Precision Oncology|March 2, 2023
Liquid Biopsies for Circulating Tumor DNA Detection May Reveal Occult Hematologic Malignancies in Patients With Solid TumorsMihaela Aldea, Marco Tagliamento, Arnaud Bayle, et al.
Nature Cancer|February 4, 2022
Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expressionLucile Vanhersecke, Maxime Brunet, Jean-Philippe Guégan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2024
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY TrialD Ross Camidge, Jair Bar, Hidehito Horinouchi, et al.
The New England Journal of Medicine|October 4, 2018
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLCScott J Antonia, Augusto Villegas, Davey Daniel, et al.
Journal of Experimental & Clinical Cancer Research : CR|December 7, 2023
Immune checkpoints are predominantly co-expressed by clonally expanded CD4+FoxP3+ intratumoral T-cells in primary human cancersDelphine Bredel, Edi Tihic, Séverine Mouraud, et al.
Pageof 59